• 20 new agreements executed, across migration technology contracts and Ensight software license agreements
• Estimated total contract value of approximately AU$2.5 million in revenue
• 75% of revenue from these new agreements to be recognised in 2025, helping Enlitic propel towards operational cashflow break even by end of 2025

Enlitic, Inc. (ASX: ENL) is pleased to announce continued commercial momentum with twenty new agreements signed year-to-date in 2025. These agreements, comprising a mix of migration technology contracts and Ensight Software License Agreements, reflect strong demand for the Company's solutions and ongoing conversion of a robust open opportunity pipeline. Subject to successful validation testing, the contracts represent an estimated total contract value of approximately AU$2.5 million in revenue for the Company, with 75% of this revenue to be recognised in 2025 with the balance to be recognised from the current period through to 2027. The new agreements contribute to Enlitic becoming operational cashflow break even by the end of 2025. Enlitic's migration business has delivered new data migration agreements for leading healthcare providers such as University of California San Francisco, Regional West Health Services, and Guy's and St. Thomas NHS Foundation Trust, among others. Enlitic has also entered into three new agreements for its Ensight solution with Alaska Radiology (Imaging Associates), National Cancer Institute Brigham & Women's Hospital/Harvard Medical School and RHCNZ Medical Imaging. Enlitic's CEO Michael Sistenich commented that these new agreements are a strong endorsement of Enlitic's strategic direction and solidify its role as a trusted partner for data standardisation and migration services.

The new agreements are expected to contribute 75% of the estimated AU$2.5 million in revenue to be recognised in the 2025 financial year, helping Enlitic propel towards operational cashflow break even by the end of 2025.

Enlitic remains focused on enabling the healthcare industry's transition to innovative, reliable, and scalable imaging solutions, and looks forward to strengthening its partnerships across the global healthcare ecosystem.